More from this creator
Other episodes by anas.anabtawi1.
More like this
If you liked this, try these.
Transcript
The full episode, in writing.
Pulmonary function tests, known as PFTs, are a series of assessments that quantify how effectively the lungs are operating. In general internal medicine, these tests are fundamental for evaluating patients who present with symptoms such as shortness of breath, wheezing, or chronic cough. Among all PFTs, spirometry is the most commonly employed tool, especially when clinicians are investigating asthma, a chronic inflammatory disease of the airways.
Asthma is characterized by recurrent symptoms including wheezing, coughing, chest tightness, and variable shortness of breath. The presence of airflow obstruction that is reversible, either spontaneously or with medication, is a hallmark of the disease. In clinical practice, spirometry offers a standardized, objective measure to confirm or exclude asthma, since relying solely on history and physical exam cannot distinguish asthma from other respiratory conditions.
Spirometry measures both the volume and speed of air that a person can inhale and exhale. The procedure requires the patient to take a deep breath to full lung capacity and then exhale as forcefully and rapidly as possible into a spirometer, a device that records the data. The two primary numbers generated from this maneuver are Forced Vital Capacity (FVC)—the total amount of air exhaled—and Forced Expiratory Volume in 1 second (FEV1)—the amount exhaled in the first second of the forced breath.
The FEV1/FVC ratio is especially crucial in diagnosing obstructive airway diseases like asthma. In healthy adults, this ratio typically falls between 70% and 80%, though it declines slightly with age. A ratio below 70% suggests the presence of airflow obstruction, which is a key feature of asthma. For example, a patient with an FEV1 of 1.8 liters and an FVC of 3.0 liters would have an FEV1/FVC ratio of 60%, supporting an obstructive pattern.
Asthma is distinct, however, because its airway obstruction is variable and often reversible. To test this, clinicians perform bronchodilator response testing. First, spirometry is conducted to capture baseline lung function. Next, the patient inhales a bronchodilator medication—a drug that relaxes the airway muscles. After about 15 minutes, spirometry is repeated. If the FEV1 increases by 12% or more and by at least 200 milliliters in absolute value, this is considered a significant bronchodilator response, supporting the diagnosis of asthma. This reversibility helps differentiate asthma from conditions like chronic obstructive pulmonary disease, where reversibility is typically less pronounced.
Beyond FEV1 and FVC, other spirometry and PFT parameters provide further insight. Peak Expiratory Flow (PEF) measures the highest flow achieved during forced exhalation. PEF is particularly useful for daily monitoring, as patients can use a peak flow meter at home to detect variability in their asthma control from day to day. However, these meters are not diagnostic tools; diagnosis relies on spirometry.
Total Lung Capacity (TLC) quantifies the maximum volume of air the lungs can hold and is measured via body plethysmography or dilution techniques. In asthma, TLC is often normal or increased due to air trapping, while in restrictive diseases like pulmonary fibrosis, TLC is reduced. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) measures how well gases diffuse across the alveolar membrane. DLCO is usually normal in asthma but can be reduced in other diseases such as pulmonary fibrosis or emphysema.
One of the key strengths of PFTs is their ability to distinguish between obstructive and restrictive patterns. In obstructive diseases like asthma, the primary problem is increased airway resistance, resulting in a reduced FEV1/FVC ratio and a scooped-out appearance on the flow-volume loop. In contrast, restrictive diseases reduce both FEV1 and FVC but maintain a normal or even elevated ratio, since both values drop in parallel.
Asthma management relies heavily on both initial diagnosis and ongoing monitoring with PFTs. Once asthma is confirmed, effective management requires a combination of lifestyle modifications and medications. Lifestyle changes may include avoiding triggers, such as allergens or tobacco smoke, and maintaining a healthy weight. Medications are prescribed according to the severity and control of symptoms. Inhaled corticosteroids are considered the foundation of long-term control, while short-acting beta2 agonists act as rescue medications during exacerbations. Adherence to the prescribed medication regimen is crucial for achieving and maintaining asthma control. Patients who consistently follow their medication plan experience fewer exacerbations, improved symptom control, and better quality of life.
The history of asthma and pulmonary function testing extends over two centuries. In the 19th century, asthma was recognized as a distinct clinical entity, mainly defined by its characteristic symptoms and episodic nature. The development of spirometry in the 20th century marked a revolution in respiratory medicine. The first spirometer provided objective measurements, allowing clinicians to move beyond subjective assessment. By the late 20th century, spirometry and other PFTs had become standard practice for diagnosing and monitoring asthma, embedded in guidelines and taught extensively in medical schools and training programs.
Programs such as the Medical Knowledge Self-Assessment Program (MKSAP) reflect the integration of PFT interpretation into internal medicine education. These programs use question banks and case studies to train practitioners in recognizing spirometry patterns, differentiating between asthma and other lung diseases, and applying test results to guide management.
Some diagnostic nuances extend beyond routine spirometry. Bronchial challenge tests, using agents like methacholine or histamine that provoke airway narrowing, are employed when routine spirometry is normal but clinical suspicion for asthma remains high. A positive challenge—demonstrating significant airway hyperresponsiveness—supports the diagnosis of asthma.
Objective assessment with spirometry is essential, as medical history and physical examination alone cannot reliably diagnose or exclude asthma. This objective measurement is particularly important in children, where symptoms can overlap with other common conditions. Spirometry is typically feasible in cooperative children aged five years and above.
Clinical guidelines recommend using PFTs not only at diagnosis but also for ongoing monitoring. Regular assessment helps clinicians identify deterioration in lung function, evaluate response to therapy, and determine if changes in treatment are necessary. For example, a patient whose FEV1 improves from 1.5 liters to 2.0 liters after starting inhaled corticosteroids demonstrates a positive response to therapy.
Peak flow variability is another aspect of monitoring. Daily changes in peak expiratory flow greater than 10% may suggest poorly controlled asthma and warrant adjustment in management.
In summary, pulmonary function tests, especially spirometry, have become indispensable tools in general internal medicine for diagnosing and managing asthma. They offer quantitative, objective data that guide both initial workup and ongoing management. A reduced FEV1/FVC ratio and significant improvement after bronchodilator administration are classic findings in asthma. Total lung capacity, diffusing capacity, and peak expiratory flow add further granularity, helping distinguish asthma from other pulmonary diseases. In 2023, asthma affected 363 million people worldwide and was responsible for 442,000 deaths, illustrating the global importance of accurate diagnosis and effective management protocols.